Rob van Leen

Ping Cao

Gerjan Kemperman

Annie Vereecken



Rob van Leen is currently a Non- Executive Board Member and Consultant/Advisor to several bodies in Medical (Bio)technology and Food, plus chairman of a Regional Investment fund in The Netherlands.

He is a former Member of the Executive Committee Royal DSM, where he also served for 13 years as the Chief Innovation Officer and before that was active in food ingredients, industrial enzymes and pharma.

He has an educational background in microbiology/biochemistry (MSc), biotechnology (PhD) and business management (MBA).


Ping Cao, currently Vice President of Business Development of Henlius, graduated from Tianjin University with a BS in Material Science & Engineering and MS in Chemical Engineering and also obtained her MS in Organic Chemistry at Michigan State University. She previously worked at Tyger Scientific, Ferro, Bristol-Myer Squibb (BMS) and Abzena, and held positions of Director of Sales and Marketing, Sr. Manager of Business Development, Associate Director of Global Manufacturing and Supply Chain, and Sr. Director of Business Development. At Tyger Scientific, Ms. Cao increased the business revenue 600% in 4 years. At BMS, she was responsible for global business development at CMO (contract manufacture operation) and accomplished significant sales growth.

Then Ping joined business development team focusing on technology transactions. She negotiated and executed 36 technology collaboration deals to expedite the company’s drug discovery and development process. As a reward for her accomplishment, Ms. Cao received the Distinguished Employee Award, Innovation Award etc. at BMS. At Abzena, she developed and executed the business strategy of offering integrated contract manufacture service of biologics and antibody drug conjugates based on company core technologies of antibody drug conjugation and humanization, which greatly enhanced the company’s business growth worldwide.

ADVISORY COUNCIL – Gerjan Kemperman

After a 10-year career at major pharmaceutical companies, Gerjan Kemperman founded ChemConnection in 2012 and took the role as CEO of the company. ChemConnection rapidly evolved to become a well-respected contract services provider serving biotech’s and mid-sized pharmaceutical companies on a global scale. At the end of 2017, ChemConnection employed a team of more than 60 with expertise in process and analytical development, cGMP manufacturing and stability studies for Active Pharmaceutical Ingredients (APIs) and nanomedicines.

In March 2018 Gerjan led the exit of ChemConnection to Ardena, a reputed contract partner delivering drug development, manufacturing, logistics, (bio)analytical services, and compilation of the regulatory dossier to pharmaceutical customers globally. Ardena was backed by Mentha Capital, an Amsterdam based Private Equity firm. Gerjan became shareholder in Ardena, a member of the Board of Directors, and I assumed the role of COO in the executive leadership team. In 2019 Ardena was sold to GHO Capital, a London based Private Equity firm in order to enable the further growth of Ardena both organically and through M&A. Currently, Gerjan is still shareholder, member of the BoD, and COO in the executive leadership team of Ardena.

ADVISORY COUNCIL – Annie Vereecken

Annie Vereecken graduated as a Pharmacist (KULeuven 1974) and clinical pathologist (1977) at the same University.
She founded a renowned clinical lab in Antwerp (AML) that was sold to Sonic Healthcare (Australia) in 2010. From that time on she actively invested in a lot of start-up, scale-ups in Life Sciences /Artificial Intelligence/Machine Learning together with Herman Verrelst (CEO Biocartis). Annie and Herman met each other on the occasion of an investment in Cartagenia that was successfully sold to Agilent in 2015.
New developments in health care and life sciences were always a point of interest .
In that way, a MedTech Fund – Heran Health Tech Fund – was set up. With the incorporation of 7 existing participations the fund took a flying start. Heran wants to be an active investor and is represented in the board of directors of the companies it is invested.